靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of AGA2118 in Postmenopausal Women with Low Bone Mineral Density
The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mass.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Lntervertebral Local Administration of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Lnterbody Fusion
The primary objective of the study is to assess the overall efficacy of a single intervertebral local administration of AGA111 in patients with degenerative disc disease undergoing lumbar interbody fusion.
/ Active, not recruiting临床3期 一项评估AGA111在退行性椎间盘疾病患者接受椎体间融合术时单次椎体间局部给药的疗效和安全性的随机、双盲、安慰剂对照的III期研究
主要目的:评估AGA111在退行性椎间盘疾病患者接受椎体间融合术时单次椎体间局部给药的总体疗效。
100 项与 安济盛生物医药技术(广州)有限公司 相关的临床结果
0 项与 安济盛生物医药技术(广州)有限公司 相关的专利(医药)
100 项与 安济盛生物医药技术(广州)有限公司 相关的药物交易
100 项与 安济盛生物医药技术(广州)有限公司 相关的转化医学